DGAP-News: True Leaf Medicine International Ltd

DGAP-News: True Leaf Medicine Announces Close of Private Placement and Debt Conversion

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Financing/Capital Increase True Leaf Medicine Announces Close of Private Placement and Debt Conversion

19.01.2016 / 15:34 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

True Leaf Medicine Announces Close of Private Placement and Debt Conversion

Vancouver, BC, January 18, 2016 - True Leaf Medicine International Ltd. (the "Company") (CSE:MJ), is pleased to announce that it has closed a private placement of 2,005,953 units at a price of $0.105 per unit, yielding gross proceeds of $210,625 to be used to facilitate a move to a larger-scale manufacturing facility in Ontario, Canada and also for general working capital.

Each unit is comprised of 1 common share and one-half of one warrant. Each whole warrant is exercisable to purchase 1 additional common share of the Company at an exercise price of $0.15 per share for a period of 24 months from the issuance date of such warrants.

A commission of 8% cash and 8% broker's warrants were payable in relation to the private placement.

The Company also announces that it has effected a conversion of $15,000 of its debt into common shares of the Company at a price of $0.105 per share (the "Debt Conversion"). The Debt Conversion resulted in the issuance of 142,857 common shares in the capital of the Company. No commission was payable in relation to the Debt Conversion.

The common shares and the warrants comprising the units are subject to a hold period of 4 months and 1 day from their date of issuance.

About True Leaf International Ltd. True Leaf Medicine International Ltd. has filed an application under Health Canada's Marihuana for Medicinal Purposes Regulations (MMPR) to become a licensed producer with a facility located in the Village of Lumby, BC. The company has passed through the preliminary and enhanced screening process of Health Canada's review and is currently awaiting a 'ready-to-build' approval.

For more information, please see True Leaf's website at www.trueleaf.com

On Behalf of the Board of Directors True Leaf Medicine International Ltd.

Michael Harcourt Chairman NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

---------------------------------------------------------------------------

19.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: True Leaf Medicine International Ltd. 32 - 100 Kalamalka Lake Road V1T 9 G1 Vernon (BC) Canada Phone: +17783899933 E-mail: kevin@trueleaf.com Internet: www.trueleaf.com ISIN: CA89785C1077, CA89785C1077 WKN: , A0Q3EE Listed: Regulated Unofficial Market in Berlin, Berlin - Equiduct Trading, Munich, Stuttgart; Open Market in Frankfurt ; Canadian Venture Exchange End of News DGAP News Service ---------------------------------------------------------------------------

430745 19.01.2016